Regulation of CD30 antigen expression and its potential significance for human disease

American Journal of Pathology

Volumn 156, Issue 5, 2000, Pages 1479-1484

  Kadin, M E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICROSATELLITE DNA; TRANSCRIPTION FACTOR;

ANTIGEN EXPRESSION; AUTOIMMUNE DISEASE; CELL PROLIFERATION; GENETIC POLYMORPHISM; HUMAN; LYMPHOCYTE ACTIVATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NOTE; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 0033838780     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65018-3     Document Type: Note

References (90)

1. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease
2. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF
3. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death
4. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells
5. The expression of the Hodgkin's disease-associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells
6. CD30 is a signal-transducing molecule that defines a subset of human CD45RO+ T-cells
7. Reciprocal regulation of CD30 expression on CD4+ T cells by IL-4 and IFN-γ
8. Opposite role for interleukin-4 and inteferon-gamma on CD30 and lymphocyte activation gene-3 (LAG-3) expression by activated naive T cells
9. Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines
10. Tumor necrosis ligand superfamily: Involvement in the pathology of malignant lymphomas
11. Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines
12. CD30 expression by CD8+ T cells producing type 2 helper cytokines: Evidence for large numbers of CD8+ CD30+ T cell clones in human immunodeficiency virus infection
13. Not only Th2 cells but also Th1 and Th0 cells express CD30 after activation
14. CD30 expression does not discriminate between human Th1- and Th2-type T cells
15. Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line
16. CD30-regulated apoptosis in murine CD8 T cells after cessation of TCR signals
17. High CD30 ligand expression by epithelial cells and Hassal's corpuscles in the medulla of the thymus
18. CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a bcl-2 sensitive pathway
19. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice
20. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines
21. Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines
22. Epstein-Barr virus and Hodgkin's disease: A correlative in situ hybridization and polymerase chain reaction study
23. Involvement of Sp1 and microsatellite repressor sequences in the transcriptional control of the human CD30 gene
24. Variation of the CGG repeat at the fragile X site results in genetic instability: Resolution of the Sherman paradox
25. Microsatellite instability in inherited and sporadic neoplasms
26. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype
27. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability
28. Transducers of life and death: TNF receptor superfamily and associated proteins
29. CD30 contains two binding sites with different specificities for members of the tumor necrosis factor-associated factor family of signal transducing proteins
30. Tumor necrosis factor receptor associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NF-kB activation
31. Induction of nuclear factor kappa B by the CD30 receptor is mediated by TRAF1 and TRAF2
32. Tumor necrosis factor-associated (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain: TRAF-2 mediates CD30-induced nuclear factor kappa B activation
33. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways
34. CD30-dependent degradation of TRAF2: Implications for negative regulation of TRAF signalling and the control of cell survival
35. Binding sites of cytoplasmic effectors TRAF1, 2 and 3 on CD30 and other members of the TNF superfamily
36. CD30 induction of human immunodeficiency virus gene transcription is mediated by TRAF2
37. Tumor necrosis factor (TNF)-mediated kinase cascades: Bifurcation of nuclear factor-kB and c-jun N-terminal kinase is mediated by TRAF2
38. MAP3K-related kinase involved in induction by TNF-α, CD95 and IL-1
39. Indentifcation and characterization of an IkB kinase
40. IkB kinase-beta: NF-kB activation and complex formation with IkB kinase-alpha and NIK
41. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation
42. IKK1 and IKK2: Cytokine-activated IkB kinases essential for NF-kB activation
43. Activation of Hodgkin cells via the CD30 receptor induces autocrine secretion of interleukin-6 engaging the NF-kappa beta transcription factor
44. Cytokines and cytokine receptors in Hodgkin's disease
45. Activation of the IkB kinase complex by MEKK1, a kinase of the JNK pathway
46. Constitutive nuclear factor-kappa B-RelA activation is required for proliferation and survival of Hodgkin's tumor cells
47. CD30 ligand expression in non-malignant and Hodgkin's disease-involved lymphoid tissues
48. Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors
49. Hodgkin's disease derived cell lines HDLM-2 and L-428: Comparison of morphology, immunological and isoenzyme profiles
50. Rare occurrence of classical Hodgkin's disease as a T Cell lymphoma
51. Detection of clonal T-cell receptor gamma-chain gene-rearrangements in Reed-Sternberg cells of classic Hodgkin's disease
52. Long-term human B cell lines dependent on interleukin-4 and antibody to CD40
53. Germinal center cells express bcl-2 protein after activation by signals which prevent their entry into apoptosis
54. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from crippled germinal center B cells
55. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family
56. Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein- 1, the Epstein-Barr virus transforming protein
57. Characterization of LMP-1's association with TRAF1, TRAF2 and TRAF3
58. Epstein-Barr Virus and a cellular signaling pathway in lymphomas from immunosuppressed patients
59. Clonal deleterious mutations in the IkBα gene in the malignant cells in Hodgkin's lymphoma
60. Death receptors: Signaling and modulation
61. The tumor necrosis factor ligand and receptor families
62. T cell receptor-dependent cell death of T ceil hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors
63. Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: A role for TNF-R1 activation by endogenous membrane-anchored TNF
64. In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts
65. A murine xenograft model for human CD30+ anaplastic large cell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1)
66. CD30-CD30 ligand interaction in primary cutaneous CD30+ T-cell lymphomas: A clue to the pathophysiology of clinical regression
67. The spectrum of Ki-1+ cutaneous lymphomas
68. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders: A proposal for classification and guidelines for management and treatment
69. Primary cutaneous large cell lymphomas: Definition of a new type of cutaneous lymphoma with a favorable prognosis: An European multicenter study on 47 patients
70. CD30/Ki-1+ lymphoproliferative disorders of the skin: Clinicopathologic correlation and statistical analysis of 86 cases
71. Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay
72. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis
73. Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma
74. In vivo CD30 expression in human diseases with predominant activation of Th2-like cells
75. CD30 expression on human CD8+ T cells isolated from peripheral blood lymphocytes of normal donors
76. CD30 expression by CD8+ T cells producing type 2 helper cytokines. Evidence for large numbers of CD8+CD30+ T cell clones in human immunodeficiency virus infection
77. Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells
78. The peripheral deletion of autorective CD8+ T cells induced by cross-presentation of self-antigens involves signalling through CD95 (Fas, Apo-1)
79. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis
80. Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity
81. High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints
82. Increased serum concentration of soluble CD30 has been observed in patients with Grave's disease and Hashimoto's thyroiditis
83. In vivo relevance of CD30 in atopic dermatitis
84. Expression of CD30 on T helper cells in the inflammatory infiltrate of acute atopic dermatitis but not of allergic contact dermatitis
85. Circulating skin-homing T cells in atopic dermatitis. Selective up-regulation of HLA-DR, interleukin-2, and CD30 and decrease after UV-A and UV-B phototherapy
86. In vivo CD30 expression in human diseases with predominant activation of Th2-like T cells
87. Activation of HIV expression by CD30 triggering in CD4+ T cells from HIV-infected individuals
88. Cross-linking of CD30 induces HIV expression in chronically infected T cells
89. Role for CD30 in HIV expression
90. CD30 cell expression and abnormal soluble CD30 serum accumulation in Omenn's syndrome: Evidence for a T helper 2-mediated condition